PD-1 Blockade in Advanced Adrenocortical Carcinoma.
Raj N, Zheng Y, Kelly V, Katz SS, Chou J, Do RKG, Capanu M, Zamarin D, Saltz LB, Ariyan CE, Untch BR, O'Reilly EM, Gopalan A, Berger MF, Olino K, Segal NH, Reidy-Lagunes DL. PD-1 Blockade in Advanced Adrenocortical Carcinoma. Journal Of Clinical Oncology 2019, 38: 71-80. PMID: 31644329, PMCID: PMC7351334, DOI: 10.1200/jco.19.01586.Peer-Reviewed Original ResearchConceptsAdvanced adrenocortical carcinomaObjective response rateAdrenocortical carcinomaObjective responseResponse rateMedian progression-free survivalMismatch repair-deficient statusTreatment-related grade 3Disease control rateManageable safety profileMedian overall survivalPD-1 blockadePercent of patientsPhase II studyPrimary end pointProgression-free survivalDurable antitumor activityLimited treatment optionsMicrosatellite stable tumorsPrior therapyAdverse eventsII studyMedian durationOverall survivalStandard therapyEfficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma.
Raj N, Zheng Y, Kelly V, Katz S, Chou J, Do R, Capanu M, Zamarin D, Ariyan C, Untch B, O'Reilly E, Gopalan A, Berger M, Olino K, Segal N, Reidy D. Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma. Journal Of Clinical Oncology 2019, 37: 4112-4112. DOI: 10.1200/jco.2019.37.15_suppl.4112.Peer-Reviewed Original ResearchAdvanced adrenocortical carcinomaSafety of pembrolizumabAdrenocortical carcinomaPD-L1Germline next-generation sequencingMedian tumor mutation burdenPhysician/patient decisionTumor PD-L1 positivityTumor PD-L1 statusMedian age 62Treatment-related AEsTumor PD-L1PD-L1 positivityPD-L1 statusSingle-center studyTumor mutation burdenAvailable tumor samplesMutations/megabaseECOG 0LFT elevationsMedian DoRMedian OSMedian PFSIntolerable toxicityPrimary endpoint